Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview March 2, 2022 Protara Therapeutics to Participate in Upcoming Investor Conferences February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer January 4, 2022 Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference November 4, 2021 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Pagination First page « Previous page ‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 Next page › Last page » Displaying 85 - 96 of 133 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview March 2, 2022 Protara Therapeutics to Participate in Upcoming Investor Conferences February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer January 4, 2022 Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference November 4, 2021 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Pagination First page « Previous page ‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 Next page › Last page » Displaying 85 - 96 of 133
May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview
March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview
February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
November 4, 2021 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
